DR KROP: So very clear data from the Europeans in a neoadjuvant study called NEOSPHERE that Luca Gianni presented last San Antonio — two San Antonios ago now — in which patients were given a taxane-based regimen — docetaxel with trastuzumab or pertuzumab or the combination, or there was actually a fourth arm that just got the two antibodies alone without chemotherapy. And in that study, the pertuzumab/trastuzumab combination with chemotherapy had a fairly markedly higher path CR rate compared to either antibody alone with chemotherapy. And that kind of fits with this general paradigm that we're starting to see in HER2-positive disease, in which dual blockade, either with pertuzumab/trastuzumab or with trastuzumab/lapatinib, seems to have additive if not synergistic benefit.